{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T19:54:57Z","timestamp":1785354897043,"version":"3.55.0"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T00:00:00Z","timestamp":1620864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012246","name":"Priority Academic Program Development of Jiangsu Higher Education Institutions","doi-asserted-by":"publisher","award":["BE2019666"],"award-info":[{"award-number":["BE2019666"]}],"id":[{"id":"10.13039\/501100012246","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Huntington's disease (HD) is a progressive neurodegenerative disorder. Generally, it is characterized by deficits in cognition, behavior, and movement. Recent studies have shown that pridopidine is a potential and effective drug candidate for the treatment of HD. In the present study, we performed a meta-analysis to evaluate the efficacy and safety of pridopidine in HD.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> The MEDLINE, EMBASE, CENTRAL, and <jats:ext-link>Clinicaltrials.gov<\/jats:ext-link> databases were searched for randomized controlled trials (RCTs) which had that evaluated pridopidine therapy in HD patients.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> We pooled data from 1,119 patients across four RCTs. Patients in the pridopidine group had a significantly lower Unified Huntington's Disease Rating Scale (UHDRS)-modified Motor Score (mMS) (MD \u22120.79, 95% CI = \u22121.46 to \u22120.11, <jats:italic>p<\/jats:italic> = 0.02) than those in the placebo group. Additionally, no differences were observed in the UHDRS-Total Motor Score (TMS) (MD \u22120.91. 95% CI = \u22122.03 to 0.21, <jats:italic>p<\/jats:italic> = 0.11) or adverse events (RR 1.06, 95% CI = 0.96 to 1.16, <jats:italic>p<\/jats:italic> = 0.24) in the pridopidine and placebo groups. In the subgroup analysis, the short-term (\u226412 weeks) and long-term (&amp;gt;12 weeks) subgroups exhibited similar efficacy and safety with no statistical significance in TMS, mMS, or adverse events. However, TMS (MD \u22121.50, 95% CI = \u22122.87 to \u22120.12, <jats:italic>p<\/jats:italic> = 0.03) and mMS (MD \u22121.03, 95% CI = \u22121.87 to \u22120.19, <jats:italic>p<\/jats:italic> = 0.02) were observed to be improved significantly when the dosage of pridopidine \u226590 mg\/day. Additionally, pridopidine (\u226590 mg\/day) increased total adverse events (RR 1.11, 95% CI = 1.00 to 1.22, <jats:italic>p<\/jats:italic> = 0.04) compared with placebo. On this basis, we analyzed the incidence of various adverse events when the dosage was \u226590 mg\/day. Nonetheless, these results were within the acceptable threshold, although patients developed symptoms, such as nasopharyngitis and insomnia.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Pridopidine improved mMS and had no statistical significance in association with TMS or adverse events. Pridopidine (\u226590 mg\/day) improved TMS and mMS but increased adverse events, such as nasopharyngitis and insomnia. More RCTs were expected to assess pridopidine in HD.<\/jats:p>","DOI":"10.3389\/fneur.2021.658123","type":"journal-article","created":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T09:44:16Z","timestamp":1620899056000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Pridopidine for the Improvement of Motor Function in Patients With Huntington's Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.3389","volume":"12","author":[{"given":"Shujun","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyu","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shouru","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qun","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,5,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/B978-0-12-801893-4.00001-8","article-title":"Genetics of Huntington disease","volume":"144","author":"Nance","year":"2017","journal-title":"Handb Clin Neurol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/S0140-6736(07)60111-1","article-title":"Huntington's disease","volume":"369","author":"Walker","year":"2007","journal-title":"Lancet."},{"key":"B3","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s12041-018-0957-1","article-title":"Huntington's disease: the coming of age","volume":"97","author":"Pandey","year":"2018","journal-title":"J Genet."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1093\/brain\/aww165","article-title":"George Huntington: a legacy of inquiry, empathy and hope","volume":"139","author":"Wexler","year":"2016","journal-title":"Brain."},{"key":"B5","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1177\/1039856218791036","article-title":"Huntington's disease: neuropsychiatric manifestations of Huntington's disease","volume":"26","author":"Goh","year":"2018","journal-title":"Australas Psychiatry."},{"key":"B6","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1093\/arclin\/acx086","article-title":"The neuropsychology of Huntington's disease","volume":"32","author":"Snowden","year":"2017","journal-title":"Arch Clin Neuropsychol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","article-title":"The Huntington's Disease Collaborative Research Group","volume":"72","year":"1993","journal-title":"Cell."},{"key":"B8","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1080\/14737175.2016.1226134","article-title":"Antipsychotic drugs in Huntington's disease","volume":"17","author":"Unti","year":"2017","journal-title":"Expert Rev Neurother."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1007\/s13311-020-00891-w","article-title":"Therapeutic update on Huntington's disease: symptomatic treatments and emerging disease-modifying therapies","volume":"17","author":"Dash","year":"2020","journal-title":"Neurotherapeutics."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/mds.26331","article-title":"Therapeutic advances in Huntington's disease","volume":"30","author":"Shannon","year":"2015","journal-title":"Mov Disord."},{"key":"B11","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s40265-016-0670-4","article-title":"Current pharmacological approaches to reduce chorea in Huntington's disease","volume":"77","author":"Coppen","year":"2017","journal-title":"Drugs."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1002\/mds.26012","article-title":"Determinants of functional disability in Huntington's disease: role of cognitive and motor dysfunction","volume":"29","author":"Ross","year":"2014","journal-title":"Mov Disord."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1002\/mds.22188","article-title":"A Europe-wide assessment of current medication choices in Huntington's disease","volume":"23","author":"Priller","year":"2008","journal-title":"Mov Disord."},{"key":"B14","doi-asserted-by":"publisher","first-page":"RRN1184","DOI":"10.1371\/currents.RRN1184","article-title":"Observing Huntington's disease: the European Huntington's disease network's REGISTRY","volume":"2","author":"Orth","year":"2010","journal-title":"PLoS Curr."},{"key":"B15","doi-asserted-by":"publisher","first-page":"RRN1260","DOI":"10.1371\/currents.RRN1260","article-title":"An International survey-based algorithm for the pharmacologic treatment of chorea in Huntington's disease","volume":"3","author":"Burgunder","year":"2011","journal-title":"PLoS Curr."},{"key":"B16","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1080\/14737175.2018.1403899","article-title":"Treatment options for chorea","volume":"18","author":"Bashir","year":"2018","journal-title":"Expert Rev Neurother."},{"key":"B17","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/mds.23953","article-title":"Pharmacologic approaches to the treatment of Huntington's disease","volume":"27","author":"Venuto","year":"2012","journal-title":"Mov Disord."},{"key":"B18","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.nbd.2016.10.006","article-title":"The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease","volume":"97","author":"Ryskamp","year":"2017","journal-title":"Neurobiol Dis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1124\/jpet.106.102905","article-title":"The dopamine stabilizers (S)-(-)-(3-methanesulfonyl-phenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-methanesulfonylphenyl)-1-propyl-piperidine (ACR16) show high in vivo D2 receptor occupancy, antipsychotic-like efficacy, and low potential for motor side effects in the rat","volume":"318","author":"Natesan","year":"2006","journal-title":"J Pharmacol Exp Ther."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/JHD-170267","article-title":"Pridopidine: overview of pharmacology and rationale for its use in Huntington's disease","volume":"7","author":"Waters","year":"2018","journal-title":"J Huntingtons Dis."},{"key":"B21","doi-asserted-by":"publisher","first-page":"5827","DOI":"10.2147\/DDDT.S65738","article-title":"Profile of pridopidine and its potential in the treatment of Huntington disease: the evidence to date","volume":"9","author":"Squitieri","year":"2015","journal-title":"Drug Des Devel Ther."},{"key":"B22","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1007\/s00702-008-0038-3","article-title":"Effects of (-)-OSU6162 and ACR16 on motor activity in rats, indicating a unique mechanism of dopaminergic stabilization","volume":"115","author":"Rung","year":"2008","journal-title":"J Neural Transm (Vienna)."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1002\/mds.25362","article-title":"A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease","volume":"28","year":"2013","journal-title":"Mov Disord."},{"key":"B24","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1097\/WNF.0b013e3181ebb285","article-title":"Efficacy and safety of the dopaminergic stabilizer pridopidine (ACR16) in patients with Huntington's disease","volume":"33","author":"Lundin","year":"2010","journal-title":"Clin Neuropharmacol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/S1474-4422(11)70233-2","article-title":"Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"10","author":"de Yebenes","year":"2011","journal-title":"Lancet Neurol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S1474-4422(18)30391-0","article-title":"Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study","volume":"18","author":"Reilmann","year":"2019","journal-title":"Lancet Neurol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ."},{"key":"B28","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1515\/revneuro-2019-0085","article-title":"Pridopidine in the treatment of Huntington's disease","volume":"31","author":"Jablonska","year":"2020","journal-title":"Rev Neurosci."},{"key":"B29","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ejphar.2010.07.023","article-title":"In vivo pharmacology of the dopaminergic stabilizer pridopidine","volume":"644","author":"Ponten","year":"2010","journal-title":"Eur J Pharmacol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"390","DOI":"10.3201\/10.3201\/eid0703.0107304","article-title":"Spoligotype database of mycobacterium tuberculosis: biogeographic distribution of shared types and epidemiologic and phylogenetic perspectives","volume":"7","author":"Sola","year":"2001","journal-title":"Emerg Infect Dis."},{"key":"B31","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/mp.2012.3","article-title":"The dopamine stabilizers ACR16 and (-)-OSU6162 display nanomolar affinities at the sigma-1 receptor","volume":"18","author":"Sahlholm","year":"2013","journal-title":"Mol Psychiatry."},{"key":"B32","doi-asserted-by":"publisher","first-page":"338","DOI":"10.3389\/fphar.2018.00338","article-title":"Pridopidine reverses phencyclidine-induced memory impairment","volume":"9","author":"Sahlholm","year":"2018","journal-title":"Front Pharmacol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/17460441.2021.1838483","article-title":"Bi-phasic dose response in the preclinical and clinical developments of sigma-1 receptor ligands for the treatment of neurodegenerative disorders","volume":"2020","author":"Maurice","year":"","journal-title":"Expert Opin Drug Discov."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s00259-020-05030-3","article-title":"Sigma-1 and dopamine D2\/D3 receptor occupancy of pridopidine in healthy volunteers and patients with Huntington disease: a [(18)F] fluspidine and [(18)F] fallypride PET study","volume":"48","author":"Grachev","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"B35","doi-asserted-by":"publisher","first-page":"3975","DOI":"10.1093\/hmg\/ddw238","article-title":"Pridopidine activates neuroprotective pathways impaired in Huntington disease","volume":"25","author":"Geva","year":"2016","journal-title":"Hum Mol Genet."},{"key":"B36","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13024-018-0259-3","article-title":"Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse","volume":"13","author":"Kusko","year":"2018","journal-title":"Mol Neurodegener."},{"key":"B37","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/nrn2911","article-title":"Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders","volume":"11","author":"Hardingham","year":"2010","journal-title":"Nat Rev Neurosci."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.658123\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T09:44:19Z","timestamp":1620899059000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.658123\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,13]]},"references-count":37,"alternative-id":["10.3389\/fneur.2021.658123"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2021.658123","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,13]]},"article-number":"658123"}}